Biogen Inc. - BIIB
About Gravity Analytica
Recent News
- 05.01.2025 - Q1 2025 Earnings Call Webcast
- 05.01.2025 - Q1 2025 Earnings Call Webcast
- 04.15.2025 - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
- 04.15.2025 - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
- 04.15.2025 - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
- 04.15.2025 - European Commission Grants Marketing Authorization for Leqembi® (lecanemab)
- 04.15.2025 - European Commission Grants Marketing Authorization for Leqembi® (lecanemab)
- 04.14.2025 - Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
- 04.14.2025 - Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
- 04.02.2025 - Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease